Artificial 'inclusion bodies' created for controlled drug release

December 19, 2019

Precision medicine is becoming increasingly important, achieving to create more efficient personalised therapies for each patient and innovative pharmacological developments. In the oncology field, for example, researchers are developing different approaches aimed at directed and controlled drug release systems, thereby diminishing toxicity to the organism.

In this sense, researchers at the CIBER's Bioengineering, Biomaterials and Nanomedicine sector (CIBER-BBN), the Institute of Biotechnology and Biomedicine of the Universitat Autònoma de Barcelona (IBB-UAB) and the Hospital Sant Pau Research Institute have developed a new type of protein biomaterial capable of a sustained release of therapeutic proteins administered subcutaneously in lab animals.

"These structures, measuring a few micrometres in diameter, contain functional proteins that are released similarly to how human hormones are released by the endocrine system", states Antonio Villaverde, researcher at the UAB and the CIBER-BBN and one of the study's coordinators.

The study is the result of a stable scientific collaboration between Antonio Villaverde's group and the group led by Ramon Mangues at the Hospital Sant Pau Research Institute. It also included the involvement of the Institute for Biological and Technological Research of the National University of Cordoba-CONICET in Argentina.

Dr Mangues, also researcher at the CIBER-BBN and co-author of the paper, explains that "the new biomaterial imitates a bacterial product commonly found in biotechnological processes known as 'inclusion bodies', pharmacologically of interest, which in this artificial version offer a wide array of therapeutic possibilities for the oncological field and any other clinical sector in which a sustained release is needed".

Researchers used as models the enzymes common to biotechnology and a nanostructured bacterial toxin directed to human colorectal cancer metastatic cells, which have been tested on animal models. "In this way, we achieved to generate as many immovable catalysts as a new anti-tumour drug with prolonged action", the leading authors of the study explain.

Enormous Clinical Potencial

The artificial protein granules developed, which had previously been proposed as "nanopills" (therapeutic pills at nanoscopic scale), imitate the action of bacterial inclusion bodies and have enormous clinical potential for vaccines and controlled-release drug delivery systems.

"We have seen that natural inclusion bodies, administered as drugs, can produce undesired immune system responses due to the inevitable contamination of the bacterial materials", researchers say. However, in this new study, the development of artificial inclusion bodies with secreton capacity "prevents many of the regulatory problems associated with the potential development of bacterial 'nanopills', and offers a transverse platform through which to obtain functional components for cosmetical and clinical uses", they add.

This study suggests that artificial inclusion bodies can become a new category of exploitable biomaterials to be used in biotechnological applications, due to the facility with which they are manufactured and the foresight of future clinical applications.
-end-


Universitat Autonoma de Barcelona

Related Bacterial Articles from Brightsurf:

The birth of a bacterial tRNA gene
The Microbial Evolutionary Dynamics Group at the Max Planck Institute for Evolutionary Biology in Plön has directly observed the birth of a tRNA gene, using experimental evolution of bacterial populations in the laboratory.

Bacterial toxin with healing effect
A bacterial toxin promoting tissue healing has been discovered by an international research team led by scientists from University of Jena (Germany).

Next frontier in bacterial engineering
A new technique overcomes a serious hurdle in the field of bacterial design and engineering.

Bacterial enzyme could become a new target for antibiotics
Scientists discover the structure of an enzyme, found in the human gut, that breaks down a component of collagen.

Influenza: combating bacterial superinfection with the help of the microbiota
Frenc researchers and from Brazilian (Belo Horizonte), Scottish (Glasgow) and Danish (Copenhagen) laboratories have shown for the first time in mice that perturbation of the gut microbiota caused by the influenza virus favours secondary bacterial superinfection.

Scientists examined bacterial cannibalism
Researchers from Sechenov University and their colleagues summarised the results of various studies devoted to the process that can be described as bacterial cannibalism.

Bacterial link in celiac disease
Researchers have discovered bacterial exposure is a potential environmental risk factor in developing celiac disease, a hereditary autoimmune-like condition that affects about one in 70 Australians.

Fractal patterns in growing bacterial colonies
Lautaro Vassallo and his co-workers in Universidad Nacional de Mar del Plata, Argentina have modelled the growth and sliding movement of bacterial colonies using a novel method in which the behaviour of each bacterium is simulated separately.

The key to unlock bacterial fusion
Researchers identify how a Chlamydia-produced protein helps bacterial compartments fuse together, thus increasing pathogenicity.

How flow shapes bacterial biofilms
EPFL biophysicists have taken a systematic look into how bacterial biofilms are affected by fluid flow.

Read More: Bacterial News and Bacterial Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.